Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous ovarian cancer-specific cytotoxic T lymphocytes

A preparation of autologous cytotoxic T lymphocytes (CTLs) genetically modified to target a not yet disclosed ovarian cancer-specific tumor-associated antigen (TAA), with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion in culture, and reintroduction into the patient, the autologous ovarian cancer-specific cytotoxic T lymphocytes (OC-CTLs) bind to and induce selective toxicity in tumor cells expressing the TAA.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	autologous OC-CTLs autologous ovarian cancer-specific CTLs
Abbreviation:	OC-CTLs

autologous ovarian cancer-specific cytotoxic T lymphocytes

Search NCI's Drug Dictionary